NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
8 trialsNCT03223103 2025-09-10
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02721043 2021-01-11
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT03643068 2018-11-06
Phase 1A Study of the Safety of KSP/QRH Dimer
University of Michigan
Phase 1 Completed
NCT01008527 2015-09-24
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00124124 2015-02-13
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
Bhardwaj, Nina, M.D.
Phase 1 Completed
NCT00798629 2012-09-24
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed